Meghan Karuturi

2.4k total citations
81 papers, 1.6k citations indexed

About

Meghan Karuturi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Meghan Karuturi has authored 81 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 31 papers in Cancer Research. Recurrent topics in Meghan Karuturi's work include Advanced Breast Cancer Therapies (34 papers), Breast Cancer Treatment Studies (28 papers) and Cancer Treatment and Pharmacology (21 papers). Meghan Karuturi is often cited by papers focused on Advanced Breast Cancer Therapies (34 papers), Breast Cancer Treatment Studies (28 papers) and Cancer Treatment and Pharmacology (21 papers). Meghan Karuturi collaborates with scholars based in United States, Israel and United Kingdom. Meghan Karuturi's co-authors include Debasish Tripathy, Naoto T. Ueno, Takeo Fujii, Bora Lim, Miho Kono, Gretchen Kimmick, Debu Tripathy, Sharon H. Giordano, Hyman B. Muss and Holly M. Holmes and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Meghan Karuturi

75 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meghan Karuturi United States	23	884	723	338	280	216	81	1.6k
Antonella Brunello Italy	23	907 1.0×	474 0.7×	252 0.7×	354 1.3×	58 0.3×	119	1.8k
Jeffrey K. Giguere United States	22	1.4k 1.6×	795 1.1×	163 0.5×	252 0.9×	273 1.3×	66	2.2k
Michelle Shayne United States	19	774 0.9×	293 0.4×	283 0.8×	268 1.0×	72 0.3×	44	1.4k
Jacqueline M. Lafky United States	24	1.1k 1.3×	251 0.3×	226 0.7×	385 1.4×	56 0.3×	60	2.0k
P. Savvides United States	20	734 0.8×	406 0.6×	148 0.4×	455 1.6×	105 0.5×	89	1.7k
Maria Theodoulou United States	22	1.0k 1.2×	381 0.5×	368 1.1×	199 0.7×	84 0.4×	41	1.6k
David Yü Greenblatt United States	27	1.1k 1.2×	423 0.6×	204 0.6×	578 2.1×	47 0.2×	51	2.6k
Thomas Ruhstaller Switzerland	29	1.7k 2.0×	949 1.3×	613 1.8×	270 1.0×	52 0.2×	85	2.9k
Gavin Marx Australia	24	662 0.7×	735 1.0×	471 1.4×	466 1.7×	99 0.5×	100	1.8k
Jennifer Kim United States	22	326 0.4×	492 0.7×	174 0.5×	324 1.2×	112 0.5×	88	1.9k

Countries citing papers authored by Meghan Karuturi

Since Specialization

Citations

This map shows the geographic impact of Meghan Karuturi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meghan Karuturi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meghan Karuturi more than expected).

Fields of papers citing papers by Meghan Karuturi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meghan Karuturi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meghan Karuturi. The network helps show where Meghan Karuturi may publish in the future.

Co-authorship network of co-authors of Meghan Karuturi

This figure shows the co-authorship network connecting the top 25 collaborators of Meghan Karuturi. A scholar is included among the top collaborators of Meghan Karuturi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meghan Karuturi. Meghan Karuturi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sullivan, M. P., et al.. (2025). Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer. Breast Cancer Research and Treatment. 211(1). 213–221.

Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2024). Abstract PO3-05-11: Enhancing the interpretation of real-world quality of life (QoL) in patients (pts) with hormone receptor positive human epidermal growth factor 2 negative (HR+/HER2−) advanced breast cancer (ABC) enrolled in the POLARIS trial. Cancer Research. 84(9_Supplement). PO3–5.

Adesoye, Taiwo, Min Yi, Susie X. Sun, et al.. (2024). Clinical Outcomes in Patients with Early Stage Node-Negative HER2-Positive Breast Cancer Receiving Upfront Surgery or Neoadjuvant Systemic Therapy. Annals of Surgical Oncology. 31(13). 8795–8801. 2 indexed citations

Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2024). Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Research and Treatment. 209(3). 613–627. 1 indexed citations

Damodaran, Senthil, Diane Liu, Jill L. Schwartz, et al.. (2023). Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). Cancer Research. 83(5_Supplement). P3–2. 2 indexed citations

Tripathy, Debu, Joanne L. Blum, Meghan Karuturi, et al.. (2023). 373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS. Annals of Oncology. 34. S332–S332. 3 indexed citations

Blum, Joanne L., David J. Gordon, Meghan Karuturi, et al.. (2023). Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Research and Treatment. 203(3). 463–475. 8 indexed citations

Ring, Alistair, Meghan Karuturi, Emily Nash Smyth, et al.. (2023). Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Advances in Therapy. 40(5). 2515–2523. 3 indexed citations

Bardia, Aditya, Virginia Kaklamani, Sharon Wilks, et al.. (2021). Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of Clinical Oncology. 39(12). 1360–1370. 67 indexed citations

10.

Nyrop, Kirsten A., Allison M. Deal, Stephanie B. Wheeler, et al.. (2021). Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer. Breast Cancer Research and Treatment. 191(2). 409–422. 15 indexed citations

11.

Bardia, Aditya, Sara A. Hurvitz, Angela DeMichele, et al.. (2021). Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clinical Cancer Research. 27(15). 4177–4185. 80 indexed citations

12.

Gelmon, Karen A., Janice M. Walshe, Reshma Mahtani, et al.. (2021). Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. The Breast. 59. 321–326. 20 indexed citations

13.

Yam, Clinton, Gaiane M. Rauch, Meghan Karuturi, et al.. (2020). A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs. 39(2). 509–515. 24 indexed citations

14.

Nyrop, Kirsten A., Allison M. Deal, Bryce B. Reeve, et al.. (2020). Patient‐reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. Cancer. 127(6). 957–967. 9 indexed citations

15.

Shachar, Shlomit Strulov, Allison M. Deal, Katherine E. Reeder‐Hayes, et al.. (2020). Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, p16INK4a. JNCI Cancer Spectrum. 4(6). pkaa082–pkaa082. 21 indexed citations

16.

Karuturi, Meghan, Holly M. Holmes, Xiudong Lei, et al.. (2019). Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. Journal of Geriatric Oncology. 10(5). 705–708. 19 indexed citations

17.

Nyrop, Kirsten A., Allison M. Deal, Shlomit Strulov Shachar, et al.. (2019). Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. Cancer. 125(17). 2945–2954. 65 indexed citations

18.

Clifton, Katherine, et al.. (2019). Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population. Breast Cancer Research and Treatment. 175(3). 667–674. 25 indexed citations

19.

Clifton, Katherine, et al.. (2018). Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. The Breast Journal. 24(4). 691–692. 8 indexed citations

20.

Karuturi, Meghan, Melisa L. Wong, Tina Hsu, et al.. (2016). Understanding cognition in older patients with cancer. Journal of Geriatric Oncology. 7(4). 258–269. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact